Search Results

You are looking at 1 - 5 of 5 items for :

  • Pharmacology x
Clear All
Open access

S. Jenkins, Manuel Carcao and Vanessa Bouskill

VIII/von Willebrand factor in von Willebrand’s disease: effects on replacement therapy. Blood 1981; 57: 25-31. 7. Pergantou H, Xafaki P, Adamtziki E, et al. The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor. Haemophilia 2012; 18: e66-7. 8. CSL Behring Canada, Inc. Humate-P® antihemophilic factor / von Willebrand factor complex (human), dried, pasteurized. Product monograph. 2014. Available from: http://www.cslbehring.ca/docs/995/828/2014-03-11_170453_E

Open access

Cesar Alberto Montaño, Maria Sol Cruz, Felipe Lemos, Alfredo Quiroz and Gerardo Rojas

. Santagostino E, Morfini M, Auerswald GK, et al. Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs. Haemophilia 2009; 15W5X: 983V9. 9. Rothschild C, Gill J, Scharrer I, Bray G. Transient inhibitors in the Recombinate PUP study. Thromb Haemost 2000; 84W1X: 145V6. 10. Lenk H; ITT Study Group. The German Registry of immune tolerance treatment in hemophiliaVV1999 update. Haematologica 2000; 85W10 SupplX: 45V7. 11. Ettingshausen CE, Kreuz W. The immune tolerance induction WITIX dose

Open access

Courtney Schroeder, Richard Fw. Barnes, Lena Volland, Sonha Nguyen and Annette von Drygalski

.1186/1477-7525-8-139. 25. Martinoli C, Della Casa Alberighi O, Di Minno G, et al. Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thromb Haemost 2013; 109: 1170-9. doi: 10.1160/TH12-11-0874. 26. Querol F, Rodriguez-Merchan EC. The role of ultrasonography in the diagnosis of the musculo-skeletal problems of haemophilia. Haemophilia 2012; 18: e215-26. doi: 10.1111/j.1365-2516.2011.02680.x. 27. Backhaus M, Burmester GR, Gerber T, et al.; Working Group

Open access

Kate Khair and Steve Chaplin

2010. 23. An evaluation of the extent and nature of nurse-led/midwifeled services in Ireland. National Council for the Professional Development of Nursing and Midwifery. (http://hdl.handle.net/10147/44772) 24. Department of Health. Strategic Framework for Role Expansion of Nurses and Midwives: Promoting Quality Patient Care. May 2011. (http://health.gov.ie/wp-content/uploads/2014/03/role_expansion_nurses_midwives.pdf) 25. Royal College of Nursing response to the All-Party Parliamentary Group on Global Health

Open access

Piotr Boguta, Dariusz Juchnowicz, Paulina Wróbel-Knybel, Agnieszka Biała-Kędra and Hanna Karakuła-Juchnowicz

(NOACs). Pharmacol Res. 2018; 135:60-79. 7. ELIQUIS, INN-apixaban. Aneks I Charakterystyka produktu leczniczego. [Cited 03.01.2019]. Accessible at: http://leki.urpl.gov.pl/files/16_Eliquis.pdf 8. Pradaxa, INN-dabigatran etexilate. Aneks I Charakterystyka produktu leczniczego [Cited 03.01.2019]. Accessible at: http://leki.urpl.gov.pl/files/25_PRADAXA_kap_tw.pdf 9. Lixiana, INN-edoxaban. Aneks I Charakterystyka produktu leczniczego. [Cited 03.01.2019]. Accessible at: http://ec.europa.eu/health/documents/community-register/2015/20150619132091/anx